Pieris Pharmaceuticals Inc. NASDAQ: PIRS Shaping-Up

Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.

TECHNICAL

After breaking-out on large meaningful volume two weeks ago, shares of Pieris Pharmaceuticals Inc. - PIRS now finds itself digesting/consolidating the recent thrust into higher ground on lower volume and in a very constructive manner.

When observing the Daily chart above, we can see that PIRS is coming out of a rounding bottom and has recaptured its 200 DMA on the recent move. In addition, we can also see that PIRS now finds itself trading above all of its important moving averages (20/50/200 DMA's), which depicts a favorable technical posture.

Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we would not be surprised if a move into the $5- $6 zone were to occur in the not too distant future.